We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of the Expression of Nogo and Reticulon Genes in Skeletal Muscle of Patients With Amyotrophic Lateral Sclerosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00213824
Recruitment Status : Terminated
First Posted : September 21, 2005
Last Update Posted : March 27, 2015
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:
This is a study of the expression of nogo and reticulon genes in the skeletal muscle of patients with amyotrophic lateral sclerosis (ALS).

Condition or disease
Amyotrophic Lateral Sclerosis

Study Design

Study Type : Observational
Actual Enrollment : 79 participants
Observational Model: Case Control
Time Perspective: Prospective
Official Title: A Study of the Expression of Nogo and Reticulon Genes in Skeletal Muscle of Patients With Amyotrophic Lateral Sclerosis
Study Start Date : February 2004
Primary Completion Date : July 2012
Study Completion Date : July 2012


Groups and Cohorts


Outcome Measures

Biospecimen Retention:   None Retained
tissue (skeletal muscle)

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
University Hospital, Strasbourg, France
Criteria

Inclusion Criteria:

  • Patients with definite ALS
  • Males or females
  • Age > 18

Exclusion Criteria:

  • Patients with other neuromuscular affections
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00213824


Locations
France
Clinique Neurologique, Service des Maladies du Système Nerveux et du Muscle, Hôpital Civil, Hôpitaux Universitaires
Strasbourg, France, 67091
Sponsors and Collaborators
University Hospital, Strasbourg, France
Investigators
Principal Investigator: Yon-Andoni Echaniz-Laguna, MD Hopitaux Universitaires de Strasbourg
More Information

Responsible Party: University Hospital, Strasbourg, France
ClinicalTrials.gov Identifier: NCT00213824     History of Changes
Other Study ID Numbers: 3142
First Posted: September 21, 2005    Key Record Dates
Last Update Posted: March 27, 2015
Last Verified: March 2015

Keywords provided by University Hospital, Strasbourg, France:
Amyotrophic lateral sclerosis
Nogo gene
reticulon genes

Additional relevant MeSH terms:
Amyotrophic Lateral Sclerosis
Sclerosis
Motor Neuron Disease
Pathologic Processes
Neurodegenerative Diseases
Nervous System Diseases
Neuromuscular Diseases
Spinal Cord Diseases
Central Nervous System Diseases
TDP-43 Proteinopathies
Proteostasis Deficiencies
Metabolic Diseases